Parnaz Merikhian
Parnaz Merikhian
University of Texas Health
Verified email at - Homepage
Cited by
Cited by
Triple-negative breast cancer: understanding Wnt signaling in drug resistance
P Merikhian, MR Eisavand, L Farahmand
Cancer cell international 21 (1), 419, 2021
MUC1 induces tamoxifen resistance in estrogen receptor-positive breast cancer
P Merikhian, R Ghadirian, L Farahmand, S Mansouri, K Majidzadeh-A
Expert Review of Anticancer Therapy 17 (7), 607-613, 2017
Significant role of MUC1 in development of resistance to currently existing anti-cancer therapeutic agents
L Farahmand, P Merikhian, N Jalili, B Darvishi, K Majidzadeh-A
Current Cancer Drug Targets 18 (8), 737-748, 2018
Monoclonal antibody-based therapeutics, targeting the epidermal growth factor receptor family: from herceptin to Pan HER
S Moradi-Kalbolandi, A Hosseinzade, M Salehi, P Merikhian, ...
Journal of Pharmacy and Pharmacology 70 (7), 841-854, 2018
Crosstalk between MUC1 and VEGF in angiogenesis and metastasis: a review highlighting roles of the MUC1 with an emphasis on metastatic and angiogenic signaling
F Khodabakhsh, P Merikhian, MR Eisavand, L Farahmand
Cancer Cell International 21 (1), 200, 2021
MUC1 is a potential target to overcome trastuzumab resistance in breast cancer therapy
A Hosseinzadeh, P Merikhian, N Naseri, MR Eisavand, L Farahmand
Cancer Cell International 22 (1), 110, 2022
Anti-cancer therapeutic strategies based on HGF/MET, EpCAM, and tumor-stromal cross talk
K Barzaman, R Vafaei, M Samadi, MH Kazemi, A Hosseinzadeh, ...
Cancer Cell International 22 (1), 259, 2022
Recombinant nanobody against MUC1 tandem repeats inhibits growth, invasion, metastasis, and vascularization of spontaneous mouse mammary tumors
P Merikhian, B Darvishi, N Jalili, MR Esmailinejad, AS Khatibi, ...
Molecular oncology 16 (2), 485-507, 2022
The system can't perform the operation now. Try again later.
Articles 1–8